SINGH SHAWN (CHIEF EXECUTIVE OFFICER) received a stock award from VISTAGEN THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/4/2021ACC: 0001415889-21-000020
DirectorOfficer· CHIEF EXECUTIVE OFFICER
Since Aug 2018
+305K
Net shares
Net buyer
$2.3K
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
305K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+5K
Price / share
$0.45
Trade value
$2.26K
% of position
16.5%
12/31/2020
30.38K→35.38K
Total
Net shares
+5K
Net value
$2.26K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/31/2020 | A · Award | +5K | $0.45 | $2.26K | 16.5% | 30.38K | 35.38K |
| Total | +5K | $2.26K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
300K shares
Shares
+300K
Strike price
1.77
Held after
300K
Exercisable
—
12/30/2020
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock300K shares | 12/30/2020 | A · Award | +300K | 1.77 | — | 300K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned26.23K
Total
26.23K indirect26.23K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 26.23K | Indirect |
| Total | 26.23K | 26.23K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported